Justin R Abbatemarco1, Robert J Fox1, Hong Li2, Daniel Ontaneda3. 1. Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, USA. 2. Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA. 3. Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: Ontaned@ccf.org.
Abstract
BACKGROUND: Vitamin D deficiency is a proposed risk factor for multiple sclerosis (MS), but its role in progressive MS is not well understood. OBJECTIVE: To examine the association between vitamin D levels and MRI features in primary progressive (PPMS) and secondary progressive MS (SPMS). METHODS: Serum 25-hydroxyvitamin D (25[OH]D) and 25-hydroxyvitamin D3 (25[OH]D3) levels were obtained from 267 subjects enrolled into the Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis (SPRINT-MS). Associations between imaging data and vitamin D levels was determined using Pearson or Spearman correlation and multivariate regression analyses. RESULTS: 267 patients (age 55.6 ± 7.4, 47.2% male, and 51.3% PPMS) were evaluated with quantitative MRI and vitamin D levels. 25(OH)D and 25(OH)D3 were similar between PPMS and SPMS. There was no significant association between vitamin D and T1/2 lesion volume and brain parenchymal fraction. Modest associations were found between 25(OH)D3 and whole brain-magnetization transfer ratio (WB-MTR, r = 0.17, p = 0.007) and normal appearing grey matter MTR (NAGM-MTR, r = 0.15, p = 0.02). CONCLUSIONS: 25(OH)D3 levels were not associated with brain volume or lesional measures in progressive MS contrary to what has been described in relapsing remitting MS. An association between WB-MTR and NAGM-MTR suggest higher vitamin D levels may exert a protective role on myelin content in progressive MS.
BACKGROUND:Vitamin D deficiency is a proposed risk factor for multiple sclerosis (MS), but its role in progressive MS is not well understood. OBJECTIVE: To examine the association between vitamin D levels and MRI features in primary progressive (PPMS) and secondary progressive MS (SPMS). METHODS: Serum 25-hydroxyvitamin D (25[OH]D) and 25-hydroxyvitamin D3 (25[OH]D3) levels were obtained from 267 subjects enrolled into the Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis (SPRINT-MS). Associations between imaging data and vitamin D levels was determined using Pearson or Spearman correlation and multivariate regression analyses. RESULTS: 267 patients (age 55.6 ± 7.4, 47.2% male, and 51.3% PPMS) were evaluated with quantitative MRI and vitamin D levels. 25(OH)D and 25(OH)D3 were similar between PPMS and SPMS. There was no significant association between vitamin D and T1/2 lesion volume and brain parenchymal fraction. Modest associations were found between 25(OH)D3 and whole brain-magnetization transfer ratio (WB-MTR, r = 0.17, p = 0.007) and normal appearing grey matter MTR (NAGM-MTR, r = 0.15, p = 0.02). CONCLUSIONS:25(OH)D3 levels were not associated with brain volume or lesional measures in progressive MS contrary to what has been described in relapsing remitting MS. An association between WB-MTR and NAGM-MTR suggest higher vitamin D levels may exert a protective role on myelin content in progressive MS.
Authors: Pavan Bhargava; Sandra Cassard; Sonya U Steele; Christina Azevedo; Daniel Pelletier; Elizabeth A Sugar; Emmanuelle Waubant; Ellen M Mowry Journal: Contemp Clin Trials Date: 2014-10-12 Impact factor: 2.226
Authors: R M Lucas; A-L Ponsonby; K Dear; P C Valery; M P Pender; B V Taylor; T J Kilpatrick; T Dwyer; A Coulthard; C Chapman; I van der Mei; D Williams; A J McMichael Journal: Neurology Date: 2011-02-08 Impact factor: 9.910
Authors: A Catharine Ross; JoAnn E Manson; Steven A Abrams; John F Aloia; Patsy M Brannon; Steven K Clinton; Ramon A Durazo-Arvizu; J Christopher Gallagher; Richard L Gallo; Glenville Jones; Christopher S Kovacs; Susan T Mayne; Clifford J Rosen; Sue A Shapses Journal: J Clin Endocrinol Metab Date: 2010-11-29 Impact factor: 5.958
Authors: Z Khaleeli; J Sastre-Garriga; O Ciccarelli; D H Miller; A J Thompson Journal: J Neurol Neurosurg Psychiatry Date: 2007-02-07 Impact factor: 10.154
Authors: Jennifer H Yang; Torge Rempe; Natalie Whitmire; Anastasie Dunn-Pirio; Jennifer S Graves Journal: Front Neurol Date: 2022-06-03 Impact factor: 4.086